NO20062682L - Farmasoytiske blandinger inneholdende forbindelser for inhibering av neoplastiske lesjoner - Google Patents

Farmasoytiske blandinger inneholdende forbindelser for inhibering av neoplastiske lesjoner

Info

Publication number
NO20062682L
NO20062682L NO20062682A NO20062682A NO20062682L NO 20062682 L NO20062682 L NO 20062682L NO 20062682 A NO20062682 A NO 20062682A NO 20062682 A NO20062682 A NO 20062682A NO 20062682 L NO20062682 L NO 20062682L
Authority
NO
Norway
Prior art keywords
compound
activity
determining
pde
cox
Prior art date
Application number
NO20062682A
Other languages
English (en)
Inventor
Li Liu
Bing Zhu
Han Li
W Joseph Thompson
Rifat Pamukcu
Gary A Piazza
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/173,375 external-priority patent/US6200771B1/en
Priority claimed from US09/366,003 external-priority patent/US6130053A/en
Priority claimed from US09/414,628 external-priority patent/US20020009764A1/en
Publication of NO20062682L publication Critical patent/NO20062682L/no
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Det beskrives en farmasøytisk blanding for behandling av neoplasi, kjennetegnet ved at den innbefatter en farmasøytisk godkjent bærer og en forbindelse selektert ved å bestemme den syklooksygenase (COX) -inhibitoriske aktiviteten til forbindelsen; bestemme den PDE-inhibitoriske aktiviteten til forbindelsen, der PDE'en er kjennetegnet ved: (e) cGMP-spesifisitet i forhold til cAMP; (f) positiv kooperativ kinetikk i nærvær av cGMP-substrat; (g) submikromolar affinitet for cGMP; og (h) mangel på sensitivitet for inkubering med renset cGMP-avhengig proteinkinase; og selektere forbindelsen som har COX-inhibitorisk aktivitet som er lavere enn nevnte PDE-aktivitet for behandling av neoplasi.
NO20062682A 1998-10-15 2006-06-09 Farmasoytiske blandinger inneholdende forbindelser for inhibering av neoplastiske lesjoner NO20062682L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/173,375 US6200771B1 (en) 1998-10-15 1998-10-15 Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US09/366,003 US6130053A (en) 1999-08-03 1999-08-03 Method for selecting compounds for inhibition of neoplastic lesions
US09/414,628 US20020009764A1 (en) 1999-10-08 1999-10-08 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds

Publications (1)

Publication Number Publication Date
NO20062682L true NO20062682L (no) 2000-04-17

Family

ID=27390268

Family Applications (2)

Application Number Title Priority Date Filing Date
NO994995A NO994995L (no) 1998-10-15 1999-10-14 FremgangsmÕte for identifisering av forbindelser for inhibering av neoplastiske lesjoner og farmasøytiske blandinger inneholdende slike forbindelser
NO20062682A NO20062682L (no) 1998-10-15 2006-06-09 Farmasoytiske blandinger inneholdende forbindelser for inhibering av neoplastiske lesjoner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO994995A NO994995L (no) 1998-10-15 1999-10-14 FremgangsmÕte for identifisering av forbindelser for inhibering av neoplastiske lesjoner og farmasøytiske blandinger inneholdende slike forbindelser

Country Status (13)

Country Link
EP (2) EP1161943A3 (no)
JP (1) JP2000186047A (no)
CN (1) CN100389829C (no)
AT (1) ATE214920T1 (no)
AU (1) AU770308B2 (no)
CA (1) CA2284853A1 (no)
DE (1) DE69901082T2 (no)
DK (1) DK0997145T3 (no)
ES (1) ES2174573T3 (no)
IL (1) IL132366A0 (no)
NO (2) NO994995L (no)
TR (1) TR199902578A3 (no)
TW (1) TWI239837B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531826A (ja) * 1998-11-25 2002-09-24 セル パスウェイズ インコーポレイテッド 新形成診断法
US6569638B1 (en) * 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
SK2142003A3 (en) * 2000-08-21 2003-07-01 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use
EP1597386A1 (en) * 2002-11-13 2005-11-23 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
ES2365847T3 (es) 2003-10-03 2011-10-11 Veijlen N.V. Uso de derivados del ácido indolacético que aumentan la concentración sérica de igf-1 para la preparación de una composición terapéutica para el tratamiento de diversas enfermedades.
US7659426B2 (en) 2003-12-01 2010-02-09 Reverse Proteomics Research Institute Co., Ltd. Target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
JP5219135B2 (ja) * 2008-07-25 2013-06-26 独立行政法人産業技術総合研究所 炎症性疾患モデル動物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69202721T2 (de) * 1991-03-08 1995-10-12 Fgn Inc Substituierte Indenylverbindungen.
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5998477A (en) * 1996-06-13 1999-12-07 Cell Pathways Inc. Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
WO1998011882A1 (en) * 1996-09-18 1998-03-26 Codon Pharmaceuticals, Inc. Pharmaceutical compositions and methods
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
TR200001687T2 (tr) * 1997-12-12 2000-10-23 Cell Pathways, Inc. Neopleasyo için N-benzil-3-indenilasetamid türevleri.

Also Published As

Publication number Publication date
CA2284853A1 (en) 2000-04-15
EP0997145B1 (en) 2002-03-27
CN1255379A (zh) 2000-06-07
DK0997145T3 (da) 2002-07-29
EP0997145A1 (en) 2000-05-03
TR199902578A2 (xx) 2000-06-21
EP1161943A2 (en) 2001-12-12
DE69901082D1 (de) 2002-05-02
AU770308B2 (en) 2004-02-19
DE69901082T2 (de) 2002-08-29
IL132366A0 (en) 2001-03-19
CN100389829C (zh) 2008-05-28
NO994995L (no) 2000-04-17
TWI239837B (en) 2005-09-21
EP1161943A3 (en) 2003-12-10
JP2000186047A (ja) 2000-07-04
ATE214920T1 (de) 2002-04-15
NO994995D0 (no) 1999-10-14
AU5401099A (en) 2000-04-20
TR199902578A3 (tr) 2000-06-21
ES2174573T3 (es) 2002-11-01

Similar Documents

Publication Publication Date Title
NO20062682L (no) Farmasoytiske blandinger inneholdende forbindelser for inhibering av neoplastiske lesjoner
BG106020A (en) Inhibitors of impdh enzyme
HK1095536A1 (en) 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane as a potent tyrosinase inhibitor
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
HUP0301269A2 (hu) Ftalazinonszármazékok és ezeket tartalmazó gyógyszerkészítmények
DE60227492D1 (de) Hemmstoffe der akt aktivität
YU76401A (sh) 1-amino triazolo(4,3-a)hinazolin-5-oni i/ili - 5-tioni koji inhibiraju fosfodiesteraze iv
HUP0100669A2 (hu) Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
DE69823648D1 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
ES2105108T3 (es) Esteroides para el tratamiento de la hipertrofia prostatica, su preparacion y su utilizacion.
DK0881300T3 (da) Metode til at identificere forbindelser til inhibition af neoplastiske læsioner
BR0113389A (pt) Compostos que inibem a atividade do fator xa
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
ATE218860T1 (de) Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
NO308829B1 (no) Anvendelse av forbindelsen finasterid for fremstilling av et preparat for behandling av kronisk prostatitt hos menn
MXPA03011399A (es) Metodos para tratar la enfermedad de alzheimer.
BR0307266A (pt) Compostos que inibem a atividade do fator xa
ES2284970T3 (es) Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer.
AR029004A1 (es) Compuesto del acido 7-acilamino-3-heteroariltio-3-cefem carboxilico y su uso para la preparacion de una composicion antibacteriana
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application